Compare DPRO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DPRO | CHRS |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.8M | 177.7M |
| IPO Year | 2019 | 2014 |
| Metric | DPRO | CHRS |
|---|---|---|
| Price | $6.48 | $1.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $15.00 | $5.51 |
| AVG Volume (30 Days) | 1.2M | ★ 1.3M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $158.69 | $73.08 |
| Revenue Next Year | $131.85 | $30.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.78 | $1.09 |
| 52 Week High | $14.37 | $2.62 |
| Indicator | DPRO | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 76.83 | 50.32 |
| Support Level | $6.07 | $1.34 |
| Resistance Level | $6.56 | $1.46 |
| Average True Range (ATR) | 0.30 | 0.09 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 92.95 | 70.00 |
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The two segments are Drones, and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.